Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05244551 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors

A Phase 1 study of Solid Tumor, sponsored by Abbisko Therapeutics Co.

Recruiting
Registry status
Phase 1
Development phase
85
Enrollment target
20
Study locations

NCT05244551 is a Phase 1 study of Solid Tumor that is actively recruiting participants, run by Abbisko Therapeutics Co. The registered enrollment target is 85 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05244551, a Phase 1 study of Solid Tumor, is actively recruiting participants, sponsored by Abbisko Therapeutics Co.

RECRUITING
Registry status
Phase 1
Development phase
85 participants
Enrollment target
20
Study locations

Study Summary

This is an open-label phase 1 study with expansion. The study will start with a dose escalation of single-agent ABSK061 administered in repeated 28-day cycles in patients with advanced solid tumors to evaluate safety and tolerability. The expansion part will investigate oral ABSK061 at the recommended dose for expansion (RDE) to further evaluate safety and tolerability among selected tumor types. Preliminary antitumor activity will also be assessed.

Conditions Studied

Solid Tumor

Interventions

  • DRUG ABSK061

Study Locations (20)

Henan

  • Henan Cancer Hospital - Zhengzhou
  • The First Affiliated Hospital of Zhengzhou University - Zhengzhou

Jilin

  • First Hospital of Jilin University - Changchun
  • JILIN Cancer Hospital - Changchun

Liaoning

  • Liaoning Province Cancer Hospital - Shenyang
  • The First Hospital of China Medical University - Shenyang

Texas

  • Mary Crowley Cancer Research - Dallas

Abbisko Therapeutics Co., Ltd. 12B Floor, Building 1, Lane 515

  • Yuan LU - Shanghai

Anhui

  • The First Affiliated Hospital of Bengbu Medical College - Bengbu

Beijing Municipality

  • Cancer Hospital Chinese Academy of Medical Sciences - Beijing

Chongqing Municipality

  • Chongqing Daping Hospital - Chongqing

Trial Details

FieldValue
Enrollment Target 85 participants
Start Date 2022-06-30
Est. Completion 2025-04-30
Phase Phase 1

Sponsor

Abbisko Therapeutics Co

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05244551

The ClinicalTrials.gov registry entry for NCT05244551 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (62% lower). The listed sponsor is Abbisko Therapeutics Co, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which ABSK061 is the first listed.

NCT05244551 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Henan, Jilin, Liaoning.

Frequently Asked Questions

What is clinical trial NCT05244551 about?

NCT05244551 is a clinical study titled "A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors". This is an open-label phase 1 study with expansion. The study will start with a dose escalation of single-agent ABSK061 administered in repeated 28-day cycles in patients with advanced solid tumors to evaluate safety and tolerability. The expansion part will investigate oral ABSK061 at the recommend...

What is the current status of trial NCT05244551?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2022-06-30. Estimated completion is 2025-04-30.

What conditions does trial NCT05244551 study?

This clinical trial studies the following conditions: Solid Tumor.

What interventions are being tested in trial NCT05244551?

The interventions under investigation include: ABSK061 (DRUG).

Who is sponsoring clinical trial NCT05244551?

This trial is sponsored by Abbisko Therapeutics Co, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05244551 being conducted?

This trial has 20 study locations across Texas, Abbisko Therapeutics Co., Ltd. 12B Floor, Building 1, Lane 515, Anhui, Beijing Municipality, Chongqing Municipality. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.